Endo Reinforces Commitment To Pain With Novel Phase II Drug License
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo licenses axomadol for chronic pain and diabetic neuropathic pain from Grunenthal; sNDA for Valstar in bladder cancer also approved.